Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: ASLAN Pharmaceuticals Limited

Market Cap 1.7M 53.52M 1.46M 1.35M 1.26M 2.37M 160M 2.4M 15.91M 6.2M 78.57M 6.37M 6.23M 272M P/E Ratio 2022
-0.49x
P/E Ratio 2023 -0.19x
Enterprise Value 7.27M 229M 6.27M 5.77M 5.42M 10.17M 687M 10.28M 68.17M 26.56M 337M 27.28M 26.7M 1.17B EV / Sales 2022
-
EV / Sales 2023 1,189,813x
Free-Float
99%
Yield 2022 *
-
Yield 2023 -
Manager TitleAgeSince
Chief Executive Officer 53 2010-12-31
Director of Finance/CFO 47 2010-10-31
Chief Tech/Sci/R&D Officer - 2022-03-14
Director TitleAgeSince
Chairman 53 2014-05-31
Chairman 66 2019-07-25
Director/Board Member 67 2021-02-17
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-2.92% - - 1.7M
-0.71%-0.29%+56.45%+107.18% 54.54B
-1.22%+5.01%+43.38%+36.69% 43.86B
-1.43%+3.47%-15.83%-20.48% 22.63B
-1.99%-3.55%-5.97%+377.60% 20.7B
-0.47%+0.61%+16.26%-36.02% 15.84B
-2.38%-3.38%+5.53%-41.88% 14.83B
-1.70%-1.68%+24.79%+172.92% 13.1B
-3.39%+2.39%+24.09% - 12.66B
+0.29%+5.10%+75.82%+105.33% 11.56B
Average -1.30%+2.14%+24.95%+87.67% 23.3B
Weighted average by Cap. -1.29%+1.41%+30.25%+86.78%

Financials

2022 2023
Net sales - 12 378.48 10.34 9.52 8.94 16.79 1.13K 16.96 112.53 43.84 555.59 45.03 44.08 1.93K
Net income -51.38M -1.62B -44.28M -40.78M -38.29M -71.88M -4.86B -72.64M -482M -188M -2.38B -193M -189M -8.24B -44.22M -1.39B -38.11M -35.09M -32.95M -61.86M -4.18B -62.51M -415M -162M -2.05B -166M -162M -7.1B
Net Debt -19.28M -608M -16.62M -15.3M -14.37M -26.97M -1.82B -27.26M -181M -70.44M -893M -72.36M -70.82M -3.09B 5.57M 176M 4.8M 4.42M 4.15M 7.8M 527M 7.88M 52.26M 20.36M 258M 20.92M 20.47M 894M
Logo ASLAN Pharmaceuticals Limited
ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The Company's portfolio is led by eblasakimab (ASLAN004), a potential human monoclonal antibody that binds to the IL-13 receptor a1 subunit (IL-13Ra1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. It is conducting a Phase II b clinical trial investigating eblasakimab as a therapeutic antibody for moderate-to-severe atopic dermatitis (AD). The Company is also developing farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be a therapy for autoimmune disease. The Company is also focused on developing antagonists of the aryl hydrocarbon receptor (AhR), an immune checkpoint inhibitor, through a joint venture.
Employees
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!